JMP Securities Reaffirms Market Outperform Rating for DBV Technologies (NASDAQ:DBVT)

JMP Securities reissued their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Tuesday morning, Benzinga reports. They currently have a $5.00 target price on the stock.

Other equities research analysts have also recently issued reports about the company. HC Wainwright restated a buy rating and set a $5.00 target price on shares of DBV Technologies in a research note on Thursday, August 1st. StockNews.com initiated coverage on DBV Technologies in a research report on Thursday, September 19th. They set a hold rating for the company.

DBV Technologies Stock Performance

DBVT opened at $0.69 on Tuesday. The firm has a market cap of $66.10 million, a P/E ratio of -0.82 and a beta of 0.68. The business’s fifty day moving average is $0.87 and its 200-day moving average is $1.08. DBV Technologies has a 52-week low of $0.50 and a 52-week high of $2.74.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The firm had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same period in the prior year, the business earned ($0.26) earnings per share. On average, research analysts predict that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.